Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Diseases, Fungal Clear all
Terminated Phase 3 Interventional

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

NCT00000730
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 10, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

NCT03672292
View directory record Official record
Conditions
Invasive Pulmonary Aspergillosis
Interventions
SCY-078, Voriconazole, Oral Placebo Tablets
Drug · Other
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jun 10, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

NCT03327727
View directory record Official record
Conditions
Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions
Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Drug
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

NCT05526911
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876, Midazolam, Digoxin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 10, 2026, 10:27 PM EDT
Completed No phase listed Observational

Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection

NCT01150721
View directory record Official record
Conditions
Mycobacterium Infections, Non-tuberculous
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

NCT00198289
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Aurexis® (tefibazumab)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
7 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, QIV, Matching Placebo for V116
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
56
States / cities
Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT

NCT04158804
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
procalcitonin
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Torrington, Connecticut • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

NCT00638365
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001, Placebo
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

NCT04684641
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Standard Dose YPT-01, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

NCT00111644
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Ceftriaxone, beta-lactam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Early Phase 1 Interventional Results available

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

NCT05027958
View directory record Official record
Conditions
Healthy, Latent Tuberculosis Infection (LTBI)
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 10:27 PM EDT
Withdrawn Phase 4 Interventional

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

NCT00636935
View directory record Official record
Conditions
Pneumocystis Carinii Pneumonia
Interventions
Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jun 10, 2026, 10:27 PM EDT
Terminated Phase 3 Interventional

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

NCT00307099
View directory record Official record
Conditions
Bacterial Infection
Interventions
Meropenem, Standard antibiotic therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine, rifapentine and moxifloxacin, control
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
San Francisco, California • New York, New York • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

NCT00005668
View directory record Official record
Conditions
Aspergillosis, Lung Diseases, Fungal
Interventions
Itraconazole oral solution
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Outcomes of Patients Not Responding to Antibiotics in the Community

NCT00245427
View directory record Official record
Conditions
Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions
all macrolide antibiotics, all beta-lactam antibiotics
Drug
Lead sponsor
CPL Associates
Other
Eligibility
Up to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

NCT00128492
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998
View directory record Official record
Conditions
Bacterial Infection
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

NCT00021567
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Interferon Gamma for Aerosol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Not applicable Interventional

A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome

NCT00002002
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimethoprim, Sulfamethoxazole, Leucovorin calcium
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Jun 10, 2026, 10:27 PM EDT